Document Detail

Effects of thyroid dysfunction on lipid profile.
Jump to Full Text
MedLine Citation:
PMID:  21660244     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Thyroid dysfunction has a great impact on lipids as well as a number of other cardiovascular risk factors. Hypothyroidism is relatively common and is associated with an unfavorable effect on lipids. Substitution therapy is beneficial for patients with overt hypothyroidism, improving lipid profile. However, whether subclinical hypothyroidism should be treated or not is a matter of debate. On the other hand, hyperthyroidism can be associated with acquired hypocholesterolemia or unexplained improvement of lipid profile. Overall, thyroid dysfunction should be taken into account when evaluating and treating dyslipidemic patients.
Authors:
C V Rizos; M S Elisaf; E N Liberopoulos
Related Documents :
17609054 - Haemoptysis due to chronic tuberculosis vs. bronchiectasis: comparison of long-term out...
6690464 - Elevated serum d-arabinitol levels in patients with sarcoidosis.
7149494 - Postpartum pleural effusion: a common radiologic finding.
19407434 - Cryptococcal pleuritis containing a high level of adenosine deaminase in a patient with...
12324674 - Analysis of induced sputum in adults with asthma: identification of subgroup with isola...
9794564 - Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxi...
Publication Detail:
Type:  Journal Article     Date:  2011-02-24
Journal Detail:
Title:  The open cardiovascular medicine journal     Volume:  5     ISSN:  1874-1924     ISO Abbreviation:  Open Cardiovasc Med J     Publication Date:  2011  
Date Detail:
Created Date:  2011-06-10     Completed Date:  2011-07-14     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  101480504     Medline TA:  Open Cardiovasc Med J     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  76-84     Citation Subset:  -    
Affiliation:
Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Open Cardiovasc Med J
Journal ID (publisher-id): TOCMJ
ISSN: 1874-1924
Publisher: Bentham Open
Article Information
Download PDF
© Rizos et al.; Licensee Bentham Open.
open-access:
Received Day: 8 Month: 12 Year: 2010
Revision Received Day: 5 Month: 1 Year: 2011
Accepted Day: 6 Month: 1 Year: 2011
Electronic publication date: Day: 24 Month: 2 Year: 2011
collection publication date: Year: 2011
Volume: 5First Page: 76 Last Page: 84
ID: 3109527
PubMed Id: 21660244
Publisher Id: TOCMJ-5-76
DOI: 10.2174/1874192401105010076

Effects of Thyroid Dysfunction on Lipid Profile
C.V Rizos
M.S Elisaf
E.N Liberopoulos*
Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece
*Address correspondence to this author at the Department of Internal Medicine, Medical School, University of Ioannina, Ioannina 45110, Greece; Tel: +30-26510-07502; Fax: +30-26510-07016; E-mail: vaglimp@yahooo.com

INTRODUCTION

Thyroid function regulates a wide array of metabolic parameters. Thyroid function significantly affects lipoprotein metabolism as well as some cardiovascular disease (CVD) risk factors, thus influencing overall CDV risk [1-3]. Indeed, even within the normal range of thyroid-stimulating hormone (TSH) values, a linear increase in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) and a linear decrease in high-density lipoprotein cholesterol (HDL-C) levels has been observed with increasing TSH [4].


MECHANISMS (FIG. 1)

Thyroid hormones induce the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is the first step in cholesterol biosynthesis. Moreover, triiodothyronine (T3) upregulates LDL receptors by controlling the LDL receptor gene activation. This T3-mediated gene activation is done by the direct binding of T3 to specific thyroid hormone responsive elements (TREs) [5]. Furthermore, T3 controls the sterol regulatory element-binding protein-2 (SREBP-2), which in turn regulates LDL receptor’s gene expression [6]. T3 has also been associated with protecting LDL from oxidation [7].

Thyroid hormones can influence HDL metabolism by increasing cholesteryl ester transfer protein (CETP) activity, which exchanges cholesteryl esters from HDL2 to the very low density lipoproteins (VLDL) and TGs to the opposite direction [8]. In addition, thyroid hormones stimulate the lipoprotein lipase (LPL), which catabolizes the TG-rich lipoproteins, and the hepatic lipase (HL), which hydrolyzes HDL2 to HDL3 and contributes to the conversion of intermediate-density lipoproteins (IDL) to LDL and in turn LDL to small dense LDL (sdLDL) [9, 10]. Another effect of T3 is the up-regulation of apolipoprotein AV (ApoAV), which plays a major role in TG regulation [11]. Indeed, increased levels of ApoAV have been associated with decreased levels of TGs [12]. Proposed mechanisms for this effect include the decrease of hepatic VLDL-TG production and the increase of plasma LPL levels and activity, resulting in increase of lipoprotein remnant generation due to enhanced LPL-mediated lipolysis of VLDL-TG [12]. Moreover, a greater clearance of lipoprotein core remnants, caused by increased hepatic uptake due to an enhanced affinity for the LDL receptor, has also been ascribed to ApoAV [12].

Beyond their effect on lipid profile thyroid hormones can equally affect a number of other metabolic parameters related to CVD risk. Indeed, thyroid function can influence adipocyte metabolism and the production of adipokines [13-15]. Hyperthyroidism has been associated with increased levels of adiponectin, whereas hypothyroidism is not associated with significant changes in adiponectin [13, 15]. Insulin resistance is also correlated with thyroid function [16-19]. TSH is positively associated with fasting and postprandial insulin concentration and negatively with insulin sensitivity [17]. Moreover, low normal FT4 levels are significantly associated with increased insulin resistance [19]. Oxidative stress is also affected by thyroid function with studies however showing controversial outcomes [7, 20]. Furthermore, endothelial [17] and cardiac function as well as atherosclerosis [21] have been positively associated with thyroid hormone levels. A positive association between TSH and body mass index (BMI) or waist circumference has also been described [22, 23]. A large population trial using data from the fourth and fifth Tromso study showed that this association between TSH and BMI was only significant in non smokers [24].

The effects of thyroid dysfunction on lipid parameters and CVD risk factors as well as the influence of substitution therapy are discussed below.


HYPOTHYROIDISM

Hypothyroidism is a common metabolic disorder in the general population. Indeed, data from the third National Health and Nutrition Examination Survey (NHANES III) showed a 4.6% prevalence of hypothyroidism in the general population, while 9.5% of the Colorado prevalence study participants had elevated levels of TSH [3]. Thyroid failure is more common in women and its prevalence rises with age. Hypothyroid patients have increased levels of TC and LDL-C [3]. Indeed, hypothyroidism is a common cause of secondary dyslipidemia [25, 26].

Overt Hypothyroidism
Lipid Profile

Although decreased thyroid function is accompanied by reduced activity of HMG-CoA reductase, TC and LDL-C levels are increased in patients with overt hypothyroidism [27-31]. This is due to the decreased LDL-receptors’ activity, resulting in decreased catabolism of LDL and IDL [32-34]. Moreover, a decrease in LPL activity is found in overt hypothyroidism, decreasing the clearance of TG-rich lipoproteins [35]. Therefore, overt hypothyroid patients may also present with elevated TG levels associated with increased levels of VLDL and occasionally fasting chylomicronemia [29-31, 34]. The VLDL and IDL particles in hypothyroidism are rich in cholesterol and apolipoprotein E, thus resembling β-VLDL particles of type III hyperlipoproteinemia. Therefore, the full-blown clinical syndrome of the type III hyperlipoproteinemia may develop in patients homozygous for the apolipoprotein E2 allele if they become hypothyroid.

Hypothyroid patients may also exhibit elevated levels of HDL-C [27] mainly due to increased concentration of HDL2 particles. Indeed, due to a reduction of HL activity a decrease in HDL2 catabolism is observed. [36]. Moreover, decreased activity of the CETP results in reduced transfer of cholesteryl esters from HDL to VLDL, thus increasing HDL-C levels [37]. Hypothyroid patients have increased lipoprotein (a) [Lp(a)] levels [38, 39], which are associated with increased CVD risk [39, 40].

Beyond the levels of LDL-C, the qualitative composition of LDL-C plays an important role in CVD development. Indeed, increased sdLDL concentration increases the risk for CVD [41]. Trials evaluating the effects of overt hypothyroidism on LDL subfractions have shown conflicting results. A study in newly-diagnosed hypothyroid patients (n=60) showed that hypothyroidism was associated with higher prevalence of sdLDL [28]. On the other hand, there have been studies showing no significant differences between overt hypothyroid patients and healthy controls regarding sdLDL levels [42, 43]. Another study evaluated the effects of short-term overt hypothyroidism on LDL subfractions [27]. Thyroidectomized patients (n=28) were withdrawn from substitution therapy for 2-3 weeks in preparation for radioactive iodine ablation. Patients exhibited an increase in LDL-C that was found to be primarily due to increases in the large LDL particles, while sdLDL did not significantly change [27].

CVD Risk

The above abnormalities of lipid metabolism associated with overt hypothyroidism predispose to the development of atherosclerotic coronary artery disease (CAD) [44, 45]. Moreover, hypothyroidism can adversely affect other CVD risk factors, further contributing to increasing CAD risk. Decreased thyroid function not only increases the number of LDL particles, but also promotes LDL oxidability [46]. Furthermore, hypothyroidism increases plasma homocysteine levels [47-50], which can be attributed to the hypothyroidism-induced decline of kidney function [51] as well as impaired methylenetetrahydrofolate reductase activity [52]. In addition, thyroid failure is strongly associated with arterial hypertension (especially diastolic) [53-55] via sympathetic and adrenal activation [53], and increased vascular stiffness [54, 56, 57]. Subjects with overt hypothyroidism also exhibit impaired endothelial function [58], increased uric acid [28] and phosphate levels [29], all of which are associated with increased CVD risk [59, 60].

In addition, an increase in carotid intima media thickness (CIMT) has been observed in hypothyroid patients [61]. Hypothyroidism is also accompanied by increased prevalence of metabolic syndrome [62] and waist-to-hip ratio [63]. Insulin resistance is increased in thyroid failure [64], while a decrease in GLUT4 glucose transporters (leading to a reduction of glucose uptake and promoting insulin resistance [65]) is observed [64]. Moreover, there are indications of increased high-sensitivity C-reactive protein (hsCRP) levels in hypothyroidism [28, 49] although there are studies which do not support this notion [31, 50].

Substitution Therapy

Administration of substitution therapy with L-thyroxine significantly improves lipid metabolism abnormalities. A period of 4-6 weeks of thyroxin replacement therapy is usually needed to correct dyslipidemia in overt hypothyroidism. In general, changes in serum lipoproteins in hypothyroid patients are correlated with changes in free T4 (FT4) [66]. A study in newly-diagnosed hypothyroid patients (n=60) showed a decrease in serum TC and LDL-C levels after thyroxine treatment [28]. However, when the effects of substitution therapy on qualitative lipid profile were assessed no change in LDL particle size was seen [28]. A more dramatic reduction of TC levels has been observed in hypothyroid patients with higher baseline TSH levels [67].

Serum HDL-C levels tend to decrease with thyroid replacement, but this is a less consistent finding [68]. Serum Lp(a) levels also tend to decrease with restoration of euthyroidism [25, 39]. Moreover, a decrease in CIMT has been observed after thyroxine treatment in hypothyroid patients [61].

The presence of overt hypothyroidism in patients with dyslipidemia is not rare. We found that 2.8% of the patients who visited our outpatient lipid clinic with dyslipidemia had elevated levels of TSH and reduced levels of FT4 [25]. After restoration of euthyroidism with levothyroxine therapy, a significant decrease of serum levels of TC and LDL-C, apolipoprotein B (ApoB) and Lp(a) was observed, while levels of HDL-C, TGs and apolipoprotein AI (ApoAI) were not significantly changed [25]. Superimposed dyslipidemia should be taken into account in cases of failure of substitution therapy to normalize the lipid profile despite the restoration of euthyroidism [1].

Hypothyroidism is one of the most common causes of secondary dyslipidemia. Therefore, before starting hypolipidemic therapy, the evaluation of thyroid function is needed. Thyroid failure is associated with increased levels of creatinine kinase (CK) [69]. Statin therapy may substantially increase levels of CK. A study examined the effects of accidentally starting statin therapy in patients with undiagnosed hypothyroidism (n=9) [70]. These patients had significantly higher CK levels (1095 U/L) compared with untreated hypothyroid patients matched for freeT4 levels (n=18; CK=395; p<0.05) [70]. Therefore, it is imperative to firstly correct thyroid dysfunction with thyroxine substitution therapy and then treat the underlying dyslipidemia with statins.

ii  Subclinical Hypothyroidism

Subclinical hypothyroidism (SH), defined as the clinical status of elevated serum TSH levels with normal levels of FT4 and FT3, is a far more common disorder than overt hypothyroidism. The prevalence of SH in the general population is estimated at 4.3% - 9% [3, 71]. SH has a higher prevalence among women and older populations [3, 72-74]. Moreover, SH may progress to overt hypothyroidism. The rate of progression is higher with the concomitant presence of thyroperoxidase antibodies (TPO-Ab) or higher levels of TSH [75].

Lipid Profile

SH is associated with increased levels of TC and LDL-C [63, 72, 74, 76-80]. In addition, some studies have shown that SH dyslipidemia may also be accompanied by increased TGs [81, 82] and decreased HDL-C levels [83]. Moreover, subjects with high normal TSH levels (2-4 mIU/L), but with positive antithyroid antibodies may also exhibit elevated cholesterol levels [84]. In a cross-sectional study we evaluated serum lipid parameters of SH patients (n=66) and age- and sex- matched euthyroid controls (n=75) [85]. Patients with SH had significantly higher levels of TC, LDL-C and ApoB, whereas levels of TGs, HDL-C and ApoAI did not differ significantly compared with euthyroid controls [85]. Similarly, results from the fifth Tromso Study showed increased levels of LDL-C in SH patients (n=84) [86].

Most studies have shown increased Lp(a) levels related to SH [85, 87, 88]. An interesting study evaluated serum Lp(a) levels along with corresponding apolipoprotein(a) [apo(a)] phenotypes, which are known to influence Lp(a) levels, in SH patients [89]. SH patients had higher Lp(a) levels compared with controls (p=0.003). Of note, no significant difference in the frequencies of apo(a) phenotypes were detected between patients with SH (n=69) and controls (n=83).

Thyroid autoimmunity may also play an important role in the elevation of Lp(a) levels. It has been reported that euthyroid males and postmenopausal females with evidence of thyroid autoimmunity (increased titers of TPO-Ab and/or thyroglobulin autoantibodies) have increased Lp(a) levels [90]. On the other hand, a study compared the levels of Lp(a) of 22 euthyroid subjects (9 male and 13 postmenopausal female) with thyroid autoimmunity with those of 64 age- and sex-matched controls without thyroid autoimmunity [91]. There were no significant differences in the values of lipid parameters, including Lp(a), between the two groups even when apo(a) phenotypes were taken into account [91]. Moreover, no significant difference in the Lp(a) levels was found in euthyroid patients with chronic renal failure regardless of the presence of thyroid autoimmunity, the apo(a) phenotype, the stage of renal failure and the mode of dialysis in end stage patients [92]. Furthermore, the presence of thyroid autoimmunity has not been shown to influence serum lipid parameters in SH subjects [85].

There is some controversy regarding the presence or the severity of SH-induced dyslipidemia. Indeed, there have been studies indicating no significant difference in lipid profile between SH patients and controls [29-31, 93]. Data from the NHANES III revealed increased levels of TC in SH patients (n=215) vs controls (n=8013) [94]. However, when adjusted for age, race, sex and the use of lipid-lowering drugs no difference was observed between SH and controls regarding lipid profile. Moreover, there have been studies questioning the effects of thyroid hormones on Lp(a) levels. Various studies have shown no difference between SH and control subjects regarding Lp(a) levels [39, 82, 95, 96]. Lee et. al compared patients covering the whole spectrum of thyroid function and found no differences in Lp(a) between groups [31]. Moreover, no correlation was found between Lp(a) levels and TSH or FT4 [31]. On the contrary, in a study with SH patients (n=38) a significant negative correlation (r=-0.31; p=0.03) was observed between FT3 levels and Lp(a) [82].

An association between lipids, thyroid function and insulin resistance has been observed [18]. The analysis of a subgroup from the Fremantle Diabetes Study (FDS) showed that the association of TSH levels and lipid profile is significant mainly in the presence of insulin resistance. Similar results were shown in a study in euthyroid subjects [97].

An interesting aspect of the potential SH-mediated dyslipidemia is the qualitative effects of thyroid hormones on lipids. A study compared SH women (n=21) with female controls (n=11) [93]. No difference was found regarding lipid profile between the 2 groups. However, decreased ratio of cholesterol/triglycerides in LDL (p<0.02) in SH subjects vs controls indicated the presence of more TG-enriched LDL particles in those subjects. On the other hand, a study in SH patients (n=57) did not reveal any differences in LDL particle size compared with controls [42].

CVD Risk

Beyond lipids, SH can have a deleterious effect on several other CVD risk factors. SH has been associated with a hypercoagulable state [77, 83]. Furthermore, SH impairs ventricular function as well as cardiovascular and respiratory adaptation to effort and decreases heart rate variability [98, 99]. Moreover, SH decreases flow-mediated vasodilation and nitric oxide (NO) availability, which are markers of endothelial function [98, 99]. An increase in CIMT has also been described in SH patients compared with controls [78, 79]. However, a study in SH patients (n=21) did not confirm such an increase in CIMT compared with euthyroid subjects [100]. Although SH patients with TPO-Ab had higher CIMT values compared with SH patients without TPO-Ab this difference was not significant [100].

A study showed a higher incidence of multi-vessel disease in angina patients (n=344) with high TSH values although TSH was not established as a predictor for coronary artery stenosis [101]. On the other hand, a study in hypothyroid patients (n=794, 90% of whom had SH) did not reveal any differences regarding carotid atherosclerosis (carotid plaques prevalence, severity and CIMT) compared with euthyroid subjects (n=1588) after adjusting for various CVD risk factors [102]. SH has also been associated with other CVD risk factors, such as increase in insulin resistance [64, 103].

SH subjects have been described to have higher plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) (which is a known CVD marker [104]) and lower HDL Lp-PLA2 (which is associated with the antiatherogenic effects of HDL [105]) activity [81]. Moreover, a negative association between free thyroxine and hsCRP levels has been described [106]. Indeed, increased hsCRP levels have been found in SH patients [49]. A study demonstrated a linear correlation between blood pressure and TSH even within the normal reference ranges [107]. However, a large cross-sectional study in SH patients (n=806) did not find any association between SH and increased blood pressure [108]. In addition, smoking may deteriorate the lipid profile in women with SH and aggravate the degree of thyroid failure, thus contributing to the development of atherosclerosis [109].

As described above, SH is positively correlated with increased prevalence of some CVD risk factors. However, it is imperative to investigate the available data on the incidence of CVD morbidity and mortality in SH subjects. A meta-analysis of 14 trials found an increase in risk of CVD (odds ratio [OR] 1.65; 95% CI 1.28-2.12) in subjects with SH [110]. An interesting study evaluated the association of SH with the incidence of congestive heart failure (CHF), CAD, stroke, peripheral artery disease and CVD or total mortality [111]. This was a prospective analysis in a longitudinal cohort study of older adults (aged 70-79 years old) from the Health, Aging, and Body Composition (HEALTH ABC) study. SH subjects (n=338) were subdivided in groups according to their TSH levels. Patients with TSH levels ≥7 mIU/L had a greater risk for CHF (p=0.006). SH was not associated with increased prevalence of stroke, peripheral artery disease and CVD mortality. However, SH subjects with TSH ≥10 mIU/L had a higher risk for myocardial infarction (MI) (hazard ratio [HR] 4.73 95% CI 1.01-22.13) and total mortality (HR 3.13 95% CI 1.11-8.79). Similarly, a recent meta-analysis found a 41% increase in all cause mortality in SH patients compared with euthyroid subjects [112]. Another study in SH patients (n=257) found a positive correlation between SH, CAD and total mortality which however was limited only to men (OR 4; 95% CI 1.4 - 11.5) [113].

Of interest are the results from studies evaluating the effects of SH in elderly populations. The Rotterdam study found an association between SH and aortic atherosclerosis (OR 1.7; 95% CI 1.1 - 2.6) and MI (OR 2.3; 95% CI 1.3 - 4) in elderly SH women [114]. Moreover, the presence of TPO-Ab increased the risk for both aortic atherosclerosis (OR 1.9; 95% CI 1.1 - 3.6) and MI (OR 3.1; 95% CI 1.5 - 6.3). However, the presence of TPO-Ab in total study population was not associated with a history of MI. On the other hand, the Cardiovascular Health Study (CHS) did not find any link between SH and CVD morbidity and mortality in an elderly SH population, although an increased incidence of atrial fibrillation was observed [115]. Moreover, a study evaluated the association of thyrotropin with disability and survival in the Leiden 85-Plus Study elderly population [116]. The results indicated that abnormally high levels of thyrotropin not only did not affect cognitive and mental status but rather prolonged life span [116].

Substitution Therapy

A beneficial effect of substitution therapy on lipid parameters and especially TC and LDL-C in some patients with SH has been shown [30, 72, 88, 117-120]. In a meta-analysis, the mean decrease of serum TC and LDL-C levels after thyroxine substitution was -7.9 mg/dL and -10 mg/dL, respectively [72]. The reduction was larger in individuals with higher pretreatment cholesterol levels and in hypothyroid individuals taking suboptimal T4 doses [72]. The fifth Tromso study [86] evaluated the effects of thyroxine (n=32) compared with placebo (n=32) in SH patients. Thyroxine was administered with a goal of TSH levels of 0.5-1.5 mIU/L. The effect of thyroxine therapy on lipid profile was a significant decrease of only ApoB levels (p<0.01). However, when examining the subgroup of patients (n=23) with post-treatment TSH levels 0.2-2 mIU/L a significant decrease in TC (p<0.05) and LDL-C (p<0.01) was also seen. Moreover, thyroxine substitution therapy may have additional advantageous effects to offer beyond the improvement of lipid profile. Indeed, a reduction in CIMT [78, 79] and improvement of endothelial function [99] has been described in SH patients after thyroxine replacement. In addition, thyroxine therapy increased HDL-associated Lp-PLA2 activity in SH subjects [81].

These findings, however, are not consistently corroborated by other studies. Indeed, some studies showed no significant effect of thyroxine therapy on lipid profile in SH patients [78, 93, 121, 122]. Interesting were the results of a study evaluating the effects of thyroxine in SH subjects (n=66) [85]. Lipid profile was not significantly altered with the exception of a decrease in HDL-C levels (p<0.05). However, in the subgroup of patients with TC ≥240 mg/dL (n=14) or TSH ≥10 mIU/L (n=18) a decrease in TC (p<0.05) and LDL-C (p<0.01) was also observed. A recent meta-analysis showed no benefits in survival or CVD mortality after substitution therapy in SH patients [123]. Moreover, thyroxine replacement did not improve quality of life, although a beneficial effect was seen in some lipid parameters and left ventricular function [123].

The beneficial effects of thyroxine substitution therapy on Lp(a) levels in SH subjects are also debated. Several studies have shown no impact of thyroxine therapy on Lp(a) levels in SH patients [39, 40, 85, 88]. However, other studies showed a significant decrease of Lp(a) levels after thyroxine treatment [89, 118]. A study with 17 SH women demonstrated a reduction of Lp(a) by 23.5% (p=0.0005) compared with baseline after substitution therapy [118]. Milionis et al. demonstrated that thyroxine treatment was effective in reducing Lp(a) levels in SH subjects (p=0.008) [89]. Of interest was that this reduction of Lp(a) levels achieved significance only in the low molecular weight apo(a) isoforms subgroup of patients [89].

Should we Treat SH Patients?

Although it is clear that thyroid replacement therapy has beneficial effects on serum lipid profile and CVD risk in overt hypothyroid patients, no clear consensus has been established regarding the treatment of SH subjects [124, 125]. This is due to the fact that there are no data from large trials on whether and to what degree does SH affect lipid profile. Moreover, data are lacking on the overall effect of substitution therapy on morbidity and mortality in SH patients. A significant query is whether all SH patients would benefit from thyroxine replacement therapy or such therapy should be reserved for selected subgroups. Furthermore, there has not been enough evidence regarding the long-term effects of thyroid replacement in SH patients and therefore no clear recommendations can be made [126].

It seems that thyroid substitution, if used, would be most beneficial in patients with prominent thyroid dysfunction (TSH levels >10 mIU/L), higher initial cholesterol levels, smokers and subjects with positive TPO-Ab. Moreover, levothyroxine treatment may play an important role in other aspects of CVD risk beyond lipids. Of note, the potential adverse effects of levothyroxine therapy should also be taken into account. Thyroid substitution may decrease HDL-C concentration, undermining the beneficial effect of TC and LDL-C reduction in these patients. Furthermore, when treating people with angina pectoris or heart disease, one should be very cautious because thyroxin therapy may exacerbate angina or promote cardiac arrhythmia.

Overall, measurement of serum TSH levels should be included in the screening of patients with dyslipidemia [1, 127, 128]. Hypercholesterolemic patients with SH may be treated with thyroxin substitution therapy, since the restoration of euthyroidism can effectively improve lipid levels, relieve certain symptoms, and may also prevent progression to overt hypothyroidism [129].


OVERT AND SUBCLINICAL HYPERTHYROIDISM

The incidence of hyperthyroidism is lower (2.2%) [3] compared with hypothyroidism in the general population. Similarly, a decreased prevalence of hyperthyroidism is evident in hyperlipidemic patients, since only 3 out of the 248 patients in our study had thyrotoxicosis [25].

Despite the increased activity of the HMG-CoA reductase, levels of TC, LDL-C, ApoB and Lp(a) tend to decrease in patients with clinical or subclinical hyperthyroidism. This is due to increased LDL receptor gene expression resulting in enhanced LDL receptor-mediated catabolism of LDL particles [130, 131]. Moreover, no difference in LDL subfraction distribution has been observed between subclinical or overt hyperthyroid versus euthyroid subjects [42]. Furthermore, hyperthyroidism results in enhanced LDL oxidability, which is related to FT4 levels [46].

A decrease in HDL-C levels is also observed in hyperthyroidism, due to increased CETP-mediated transfer of cholesteryl esters from HDL to VLDL and increased HL-mediated catabolism of HDL2 [130, 131]. Triglyceride levels remain unchanged. On the other hand, no changes in blood pressure [108], Lp(a) [31] or hsCRP levels [31] have been described in hyperthyroid patients. However, an increase in factor X activity has been observed in subclinical hyperthyroidism patients, indicating a hypercoagulable state [77]. Therapy of clinical hyperthyroidism results in restoration of those alterations of lipid metabolism [130, 131], while the effects of treatment of subclinical hyperthyroidism subjects are not yet clear [132].

Iatrogenic hyperthyroidism has been associated with MI in subjects without coronary stenosis [133, 134]. Similarly, there have been case reports associating subclinical hyperthyroidism with MI [135], recurrent pulmonary embolism [136] and atrial fibrillation [135, 136].

Hyperthyroidism not only consists a significant cause of acquired hypobetalipoproteinemia, but it can also be the underlying cause of unexpected improvement of lipid profile in hyperlipidemic patients [137]. In the latter case, therapy of thyrotoxicosis restores the lipid parameters to the previously elevated levels [137].


CONCLUSION

Thyroid dysfunction can have an important effect on lipid profile [138]. Biochemical screening for thyroid dysfunction is critical in all dyslipidemic patients, as well as in all patients with unexpected improvement or worsening of their lipid profile. Underlying thyroid disorders should be recognized and treated in this setting.

There have been studies suggesting that screening for thyroid dysfunction is cost effective [139]. The American Thyroid Association recommends that adults be screened for thyroid dysfunction by measurement of the serum TSH concentration, beginning at age 35 years and every 5 years thereafter [140]. On the other hand, the U.S. Preventive Services Task Force concludes that the evidence is insufficient to recommend for or against routine screening for thyroid disease in adults [141].

There is a need for large studies designed to answer the question whether thyroid abnormalities (and especially SH) are associated with CVD and whether restoration of euthyroidism might influence morbidity and mortality.


REFERENCES
1. Duntas LH. Thyroid disease and lipidsThyroidYear: 2002122879312034052
2. Friis T,Pedersen LR. Serum lipids in hyper- and hypothyroidism before and after treatmentClin Chim ActaYear: 1987162155632435434
3. Canaris GJ,Manowitz NR,Mayor G,Ridgway EC. The Colorado thyroid disease prevalence studyArch Intern MedYear: 20001605263410695693
4. Asvold BO,Vatten LJ,Nilsen TI,Bjoro T. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT StudyEur J EndocrinolYear: 2007156181617287407
5. Bakker O,Hudig F,Meijssen S,Wiersinga WM. Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor geneBiochem Biophys Res CommunYear: 1998249517219712728
6. Shin DJ,Osborne TF. Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory Element-Binding Protein-2 (SREBP-2)J Biol ChemYear: 200327834114812829694
7. Faure P,Oziol L,Artur Y,Chomard P. Thyroid hormone (T3) and its acetic derivative (TA3) protect low-density lipoproteins from oxidation by different mechanismsBiochimieYear: 200486411815283976
8. Lagrost L. Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studiesBiochim Biophys ActaYear: 19941215209367811705
9. Kuusi T,Saarinen P,Nikkila EA. Evidence for the role of hepatic endothelial lipase in the metabolism of plasma high density lipoprotein2 in manAtherosclerosisYear: 198036589937417375
10. Santamarina-Fojo S,Gonzalez-Navarro H,Freeman L,Wagner E,Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesisArterioscler Thromb Vasc BiolYear: 2004241750415284087
11. Prieur X,Huby T,Coste H,Schaap FG,Chapman MJ,Rodriguez JC. Thyroid hormone regulates the hypotriglyceridemic gene APOA5J Biol ChemYear: 2005280275334315941710
12. Rensen PC,van Dijk KW,Havekes LM. Apolipoprotein AV: low concentration, high impactArterioscler Thromb Vasc BiolYear: 2005252445716306435
13. Iglesias P,Diez JJ. Influence of thyroid dysfunction on serum concentrations of adipocytokinesCytokineYear: 200740617018006329
14. Viguerie N,Millet L,Avizou S,Vidal H,Larrouy D,Langin D. Regulation of human adipocyte gene expression by thyroid hormoneJ Clin Endocrinol MetabYear: 200287630411836296
15. Hsieh CJ,Wang PW. Serum concentrations of adiponectin in patients with hyperthyroidism before and after control of thyroid functionEndocr JYear: 2008554899418469483
16. Crunkhorn S,Patti ME. Links between thyroid hormone action, oxidative metabolism, and diabetes risk?ThyroidYear: 2008182273718279023
17. Fernandez-Real JM,Lopez-Bermejo A,Castro A,Casamitjana R,Ricart W. Thyroid function is intrinsically linked to insulin sensitivity and endothelium-dependent vasodilation in healthy euthyroid subjectsJ Clin Endocrinol MetabYear: 20069133374316804039
18. Chubb SA,Davis WA,Davis TM. Interactions among thyroid function, insulin sensitivity, and serum lipid concentrations: the Fremantle diabetes studyJ Clin Endocrinol MetabYear: 20059053172015985488
19. Roos A,Bakker SJ,Links TP,Gans RO,Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjectsJ Clin Endocrinol MetabYear: 200792491617090642
20. Venditti P,Di Meo S. Thyroid hormone-induced oxidative stressCell Mol Life SciYear: 2006634143416389448
21. Auer J,Berent R,Weber T,Lassnig E,Eber B. Thyroid function is associated with presence and severity of coronary atherosclerosisClin CardiolYear: 2003265697314677810
22. De Pergola G,Ciampolillo A,Paolotti S,Trerotoli P,Giorgino R. Free triiodothyronine and thyroid stimulating hormone are directly associated with waist circumference, independently of insulin resistance, metabolic parameters and blood pressure in overweight and obese womenClin Endocrinol (Oxf)Year: 200767265917547687
23. Knudsen N,Laurberg P,Rasmussen LB,et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the populationJ Clin Endocrinol MetabYear: 20059040192415870128
24. Nyrnes A,Jorde R,Sundsfjord J. Serum TSH is positively associated with BMIInt J Obes (Lond)Year: 200630100516189501
25. Tsimihodimos V,Bairaktari E,Tzallas C,Miltiadus G,Liberopoulos E,Elisaf M. The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinicThyroidYear: 19999365810319942
26. Stone NJ. Secondary causes of hyperlipidemiaMed Clin North AmYear: 199478117418283927
27. Pearce EN,Wilson PW,Yang Q,Vasan RS,Braverman LE. Thyroid function and lipid subparticle sizes in patients with short-term hypothyroidism and a population-based cohortJ Clin Endocrinol MetabYear: 2008938889418073305
28. Abbas JM,Chakraborty J,Akanji AO,Doi SA. Hypothyroidism results in small dense LDL independent of IRS traits and hypertriglyceridemiaEndocr JYear: 200855381918385530
29. Al-Tonsi AA,Abdel-Gayoum AA,Saad M. The secondary dyslipidemia and deranged serum phosphate concentration in thyroid disordersExp Mol PatholYear: 200476182715010297
30. Teixeira Pde F,Reuters VS,Ferreira MM,et al. Lipid profile in different degrees of hypothyroidism and effects of levothyroxine replacement in mild thyroid failureTransl ResYear: 20081512243118355770
31. Lee WY,Suh JY,Rhee EJ,Park JS,Sung KC,Kim SW. Plasma CRP, apolipoprotein A-1, apolipoprotein B and Lp(a) levels according to thyroid function statusArch Med ResYear: 200435540515631881
32. Walton KW,Scott PJ,Dykes PW,Davies JW. The significance of alterations in serum lipids in thyroid dysfunction. II. Alterations of the metabolism and turnover of 131-I-low-density lipoproteins in hypothyroidism and thyrotoxicosisClin SciYear: 196529217385840973
33. Thompson GR,Soutar AK,Spengel FA,Jadhav A,Gavigan SJ,Myant NB. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivoProc Natl Acad Sci USAYear: 198178259156264482
34. Abrams JJ,Grundy SM. Cholesterol metabolism in hypothyroidism and hyperthyroidism in manJ Lipid ResYear: 198122323387240961
35. Nikkila EA,Kekki M. Plasma triglyceride metabolism in thyroid diseaseJ Clin InvestYear: 1972512103144341014
36. Lam KS,Chan MK,Yeung RT. High-density lipoprotein cholesterol, hepatic lipase and lipoprotein lipase activities in thyroid dysfunction--effects of treatmentQ J MedYear: 198659513213763814
37. Dullaart RP,Hoogenberg K,Groener JE,Dikkeschei LD,Erkelens DW,Doorenbos H. The activity of cholesteryl ester transfer protein is decreased in hypothyroidism: a possible contribution to alterations in high-density lipoproteinsEur J Clin InvestYear: 19902058172127747
38. de Bruin TW,van Barlingen H,van Linde-Sibenius Trip M,van Vuurst de Vries AR,Akveld MJ,Erkelens DW. Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjectsJ Clin Endocrinol MetabYear: 19937612168421075
39. Tzotzas T,Krassas GE,Konstantinidis T,Bougoulia M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatmentThyroidYear: 200010803811041458
40. Klausen IC,Nielsen FE,Hegedus L,Gerdes LU,Charles P,Faergeman O. Treatment of hypothyroidism reduces low-density lipoproteins but not lipoprotein(a)MetabolismYear: 19924191141386404
41. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculationYear: 2002106314342112485966
42. Kim CS,Kang JG,Lee SJ,et al. Relationship of low-density lipoprotein (LDL) particle size to thyroid function status in KoreansClin Endocrinol (Oxf)Year: 200971130619178521
43. Roscini AR,Lupattelli G,Siepi D,Pagliaricci S,Pirro M,Mannarino E. Low-density lipoprotein size in primary hypothyroidism. Effects of hormone replacement therapyAnn Nutr MetabYear: 199943374910725771
44. Tunbridge WM,Evered DC,Hall R,et al. Lipid profiles and cardiovascular disease in the Whickham area with particular reference to thyroid failureClin Endocrinol (Oxf)Year: 19777495508598015
45. Pucci E,Chiovato L,Pinchera A. Thyroid and lipid metabolismInt J Obes Relat Metab DisordYear: 200024Suppl 2S1091210997623
46. Costantini F,Pierdomenico SD,De Cesare D,et al. Effect of thyroid function on LDL oxidationArterioscler Thromb Vasc BiolYear: 19981873279598831
47. Morris MS,Bostom AG,Jacques PF,Selhub J,Rosenberg IH. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination SurveyAtherosclerosisYear: 200115519520011223442
48. Bicikova M,Tallova J,Hill M,Vanuga A,Putz Z,Tomandl J. Effect of treatment of hypothyroidism on the plasma concentrations of neuroactive steroids and homocysteineClin Chem Lab MedYear: 200139753711592446
49. Christ-Crain M,Meier C,Guglielmetti M,et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trialAtherosclerosisYear: 20031663798612535752
50. Mayer O Jr,Simon J,Filipovsky J,Plaskova M,Pikner R. Hypothyroidism in coronary heart disease and its relation to selected risk factorsVasc Health Risk ManagYear: 2006249950617323605
51. Kreisman SH,Hennessey JV. Consistent reversible elevations of serum creatinine levels in severe hypothyroidismArch Intern MedYear: 199915979829892334
52. Cimino JA,Jhangiani S,Schwartz E,Cooperman JM. Riboflavin metabolism in the hypothyroid human adultProc Soc Exp Biol MedYear: 198718415133809170
53. Fommei E,Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humansJ Clin Endocrinol MetabYear: 2002871996200011994331
54. Dernellis J,Panaretou M. Effects of thyroid replacement therapy on arterial blood pressure in patients with hypertension and hypothyroidismAm Heart JYear: 20021437182411923811
55. Klein I. Thyroid hormone and the cardiovascular systemAm J MedYear: 19908863172189307
56. Hamano K,Inoue M. Increased risk for atherosclerosis estimated by pulse wave velocity in hypothyroidism and its reversal with appropriate thyroxine treatmentEndocr JYear: 2005529510115758564
57. Dagre AG,Lekakis JP,Papaioannou TG,et al. Arterial stiffness is increased in subjects with hypothyroidismInt J CardiolYear: 20051031616061115
58. Lekakis J,Papamichael C,Alevizaki M,et al. Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) valuesThyroidYear: 1997741149226212
59. Feig DI,Kang DH,Johnson RJ. Uric acid and cardiovascular riskN Engl J MedYear: 200835918112118946066
60. Caudarella R,Vescini F,Buffa A,Francucci CM. Hyperphosphatemia: effects on bone metabolism and cardiovascular riskJ Endocrinol InvestYear: 200730293417721071
61. Nagasaki T,Inaba M,Henmi Y,et al. Decrease in carotid intima-media thickness in hypothyroid patients after normalization of thyroid functionClin Endocrinol (Oxf)Year: 2003596071214616885
62. Raterman HG,van Eijk IC,Voskuyl AE,et al. The metabolic syndrome is amplified in hypothyroid rheumatoid arthritis patients: a cross sectional studyAnn Rheum DisYear: 201069394219103637
63. Jung CH,Sung KC,Shin HS,et al. Thyroid dysfunction and their relation to cardiovascular risk factors such as lipid profile, hsCRP, and waist hip ratio in KoreaKorean J Intern MedYear: 2003181465314619383
64. Maratou E,Hadjidakis DJ,Kollias A,et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidismEur J EndocrinolYear: 20091607859019141606
65. Shepherd PR,Kahn BB. Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitusN Engl J MedYear: 19993412485710413738
66. Wiseman SA,Powell JT,Humphries SE,Press M. The magnitude of the hypercholesterolemia of hypothyroidism is associated with variation in the low density lipoprotein receptor geneJ Clin Endocrinol MetabYear: 199377108128100826
67. Elder J,McLelland A,O'Reilly DS,Packard CJ,Series JJ,Shepherd J. The relationship between serum cholesterol and serum thyrotropin, thyroxine and tri-iodothyronine concentrations in suspected hypothyroidismAnn Clin BiochemYear: 199027Pt 211032327707
68. Verdugo C,Perrot L,Ponsin G,Valentin C,Berthezene F. Time-course of alterations of high density lipoproteins (HDL) during thyroxine administration to hypothyroid womenEur J Clin InvestYear: 19871731363117568
69. Beyer IW,Karmali R,Demeester-Mirkine N,Cogan E,Fuss MJ. Serum creatine kinase levels in overt and subclinical hypothyroidismThyroidYear: 199881029319848718
70. Tokinaga K,Oeda T,Suzuki Y,Matsushima Y. HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidismEndocr JYear: 200653401516723812
71. Hollowell JG,Staehling NW,Flanders WD,et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)J Clin Endocrinol MetabYear: 2002874899911836274
72. Danese MD,Ladenson PW,Meinert CL,Powe NR. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literatureJ Clin Endocrinol MetabYear: 2000852993300110999775
73. Samuels MH. Subclinical thyroid disease in the elderlyThyroidYear: 19988803139777754
74. Luboshitzky R,Aviv A,Herer P,Lavie L. Risk factors for cardiovascular disease in women with subclinical hypothyroidismThyroidYear: 200212421512097204
75. Vanderpump MP,Tunbridge WM,French JM,et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham SurveyClin Endocrinol (Oxf)Year: 19954355687641412
76. Tanis BC,Westendorp GJ,Smelt HM. Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studiesClin Endocrinol (Oxf)Year: 19964464398759176
77. Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activityClin Endocrinol (Oxf)Year: 200664323916487444
78. Duman D,Demirtunc R,Sahin S,Esertas K. The effects of simvastatin and levothyroxine on intima-media thickness of the carotid artery in female normolipemic patients with subclinical hypothyroidism: a prospective, randomized-controlled studyJ Cardiovasc Med (Hagerstown)Year: 2007810071118163011
79. Monzani F,Caraccio N,Kozakowa M,et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- controlled studyJ Clin Endocrinol MetabYear: 200489209910615126526
80. Walsh JP,Bremner AP,Bulsara MK,et al. Thyroid dysfunction and serum lipids: a community-based studyClin Endocrinol (Oxf)Year: 200563670516343102
81. Milionis HJ,Tambaki AP,Kanioglou CN,Elisaf MS,Tselepis AD,Tsatsoulis A. Thyroid substitution therapy induces high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patients with subclinical hypothyroidism: a potential antiatherogenic effectThyroidYear: 2005154556015929667
82. Toruner F,Altinova AE,Karakoc A,et al. Risk factors for cardiovascular disease in patients with subclinical hypothyroidismAdv TherYear: 200825430718484201
83. Erdem TY,Ercan M,Ugurlu S,Balci H,Acbay O,Gundogdu S. Plasma viscosity, an early cardiovascular risk factor in women with subclinical hypothyroidismClin Hemorheol MicrocircYear: 2008382192518334776
84. Michalopoulou G,Alevizaki M,Piperingos G,et al. High serum cholesterol levels in persons with 'high-normal' TSH levels: should one extend the definition of subclinical hypothyroidism?Eur J EndocrinolYear: 199813814159506856
85. Efstathiadou Z,Bitsis S,Milionis HJ,et al. Lipid profile in subclinical hypothyroidism: is L-thyroxine substitution beneficial?Eur J EndocrinolYear: 20011457051011720894
86. Iqbal A,Jorde R,Figenschau Y. Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromso StudyJ Intern MedYear: 2006260536116789979
87. Kung AW,Pang RW,Janus ED. Elevated serum lipoprotein(a) in subclinical hypothyroidismClin Endocrinol (Oxf)Year: 19954344597586619
88. Caraccio N,Ferrannini E,Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled studyJ Clin Endocrinol MetabYear: 2002871533811932277
89. Milionis HJ,Efstathiadou Z,Tselepis AD,et al. Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxineThyroidYear: 200313365912804105
90. Lotz H,Salabe GB. Lipoprotein(a) increase associated with thyroid autoimmunityEur J EndocrinolYear: 199713687919037132
91. Bairaktari ET,Tselepis AD,Millionis HJ,Elisaf MS. Lipoprotein (a) levels, apolipoprotein (a) phenotypes and thyroid autoimmunityEur J EndocrinolYear: 1999140474610229916
92. Bairaktari ET,Milionis HJ,Katopodis K,et al. Lipoprotein (a), Apolipoprotein (a) phenotypes, and thyroid autoimmunity in uremic patientsEndocrinologistYear: 20001038388
93. Brenta G,Berg G,Arias P,et al. Lipoprotein alterations, hepatic lipase activity, and insulin sensitivity in subclinical hypothyroidism: response to L-T(4) treatmentThyroidYear: 2007174536017542675
94. Hueston WJ,Pearson WS. Subclinical hypothyroidism and the risk of hypercholesterolemiaAnn Fam MedYear: 20042351515335135
95. Yildirimkaya M,Ozata M,Yilmaz K,Kilinc C,Gundogan MA,Kutluay T. Lipoprotein(a) concentration in subclinical hypothyroidism before and after levo-thyroxine therapyEndocr JYear: 19964373169075615
96. Lippi G,Targher G,Montagnana M,Salvagno GL,Guidi GC. Relationship between lipoprotein(a) and thyroid function status in the general populationArch Med ResYear: 200738905617923276
97. Bakker SJ,ter Maaten JC,Popp-Snijders C,Slaets JP,Heine RJ,Gans RO. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjectsJ Clin Endocrinol MetabYear: 20018612061111238510
98. Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidismThyroidYear: 2000106657911014311
99. Taddei S,Caraccio N,Virdis A,et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapyJ Clin Endocrinol MetabYear: 2003883731712915662
100. Cabral MD,Teixeira PF,Silva NA,et al. Normal flow-mediated vasodilatation of the brachial artery and carotid artery intima-media thickness in subclinical hypothyroidismBraz J Med Biol ResYear: 2009424263219377791
101. Yun KH,Jeong MH,Oh SK,et al. Relationship of thyroid stimulating hormone with coronary atherosclerosis in angina patientsInt J CardiolYear: 2007122566017222925
102. Chiche F,Jublanc C,Coudert M,Carreau V,Kahn JF,Bruckert E. Hypothyroidism is not associated with increased carotid atherosclerosis when cardiovascular risk factors are accounted for in hyperlipidemic patientsAtherosclerosisYear: 20092032697618649881
103. Dessein PH,Joffe BI,Stanwix AE. Subclinical hypothyroidism is associated with insulin resistance in rheumatoid arthritisThyroidYear: 200414443615242571
104. Packard CJ,O'Reilly DS,Caslake MJ,et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study GroupN Engl J MedYear: 200034311485511036120
105. Mertens A,Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosisFASEB JYear: 20011520738411641234
106. Jublanc C,Bruckert E,Giral P,et al. Relationship of circulating C-reactive protein levels to thyroid status and cardiovascular risk in hyperlipidemic euthyroid subjects: low free thyroxine is associated with elevated hsCRPAtherosclerosisYear: 200417271114709351
107. Asvold BO,Bjoro T,Nilsen TI,Vatten LJ. Association between blood pressure and serum thyroid-stimulating hormone concentration within the reference range: a population-based studyJ Clin Endocrinol MetabYear: 200792841517200168
108. Duan Y,Peng W,Wang X,et al. Community-based study of the association of subclinical thyroid dysfunction with blood pressureEndocrineYear: 20093513614219130316
109. Muller B,Zulewski H,Huber P,Ratcliffe JG,Staub JJ. Impaired action of thyroid hormone associated with smoking in women with hypothyroidismN Engl J MedYear: 199533396497666915
110. Rodondi N,Aujesky D,Vittinghoff E,Cornuz J,Bauer DC. Subclinical hypothyroidism and the risk of coronary heart disease: a meta-analysisAm J MedYear: 20061195415116828622
111. Rodondi N,Newman AB,Vittinghoff E,et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and deathArch Intern MedYear: 20051652460616314541
112. Haentjens P,Van Meerhaeghe A,Poppe K,Velkeniers B. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studiesEur J EndocrinolYear: 20081593294118511471
113. Imaizumi M,Akahoshi M,Ichimaru S,et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidismJ Clin Endocrinol MetabYear: 20048933657015240616
114. Hak AE,Pols HA,Visser TJ,Drexhage HA,Hofman A,Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam StudyAnn Intern MedYear: 2000132270810681281
115. Cappola AR,Fried LP,Arnold AM,et al. Thyroid status, cardiovascular risk, and mortality in older adultsJAMAYear: 200629510334116507804
116. Gussekloo J,van Exel E,de Craen AJ,Meinders AE,Frolich M,Westendorp RG. Thyroid status, disability and cognitive function, and survival in old ageJAMAYear: 20042922591915572717
117. Mikhail GS,Alshammari SM,Alenezi MY,Mansour M,Khalil NA. Increased atherogenic low-density lipoprotein cholesterol in untreated subclinical hypothyroidismEndocr PractYear: 200814570518753099
118. Ganotakis ES,Mandalaki K,Tampakaki M,et al. Subclinical hypothyroidism and lipid abnormalities in older women attending a vascular disease prevention clinic: effect of thyroid replacement therapyAngiologyYear: 2003545697614565632
119. Meier C,Staub JJ,Roth CB,et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study)J Clin Endocrinol MetabYear: 2001864860611600554
120. Razvi S,Ingoe L,Keeka G,Oates C,McMillan C,Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trialJ Clin Endocrinol MetabYear: 20079217152317299073
121. Duman D,Sahin S,Esertas K,Demirtunc R. Simvastatin improves endothelial function in patents with subclinical hypothyroidismHeart VesselsYear: 200722889317390202
122. Kong WM,Sheikh MH,Lumb PJ,et al. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidismAm J MedYear: 20021123485411904108
123. Villar HC,Saconato H,Valente O,Atallah AN. Thyroid hormone replacement for subclinical hypothyroidismCochrane Database Syst RevYear: 2007 CD003419.
124. Fatourechi V. Subclinical hypothyroidism: an update for primary care physiciansMayo Clin ProcYear: 200984657119121255
125. Biondi B,Cooper DS. The clinical significance of subclinical thyroid dysfunctionEndocr RevYear: 2008297613117991805
126. Feldt-Rasmussen U. Is the treatment of subclinical hypothyroidism beneficial?Nat Clin Pract Endocrinol MetabYear: 2009586719165220
127. Cooper DS. Subclinical thyroid disease: a clinician's perspectiveAnn Intern MedYear: 199812913589669974
128. Helfand M,Redfern CC. Clinical guideline, part 2. Screening for thyroid disease: an update. American College of PhysiciansAnn Intern MedYear: 1998129144589669977
129. Ayala AR,Danese MD,Ladenson PW. When to treat mild hypothyroidismEndocrinol Metab Clin North AmYear: 20002939941510874537
130. Kung AW,Pang RW,Lauder I,Lam KS,Janus ED. Changes in serum lipoprotein(a) and lipids during treatment of hyperthyroidismClin ChemYear: 199541226317874776
131. Aviram M,Luboshitzky R,Brook JG. Lipid and lipoprotein pattern in thyroid dysfunction and the effect of therapyClin BiochemYear: 1982156267067079
132. Cooper DS. Approach to the patient with subclinical hyperthyroidismJ Clin Endocrinol MetabYear: 2007923917209221
133. Bergeron GA,Goldsmith R,Schiller NB. Myocardial infarction, severe reversible ischemia, and shock following excess thyroid administration in a woman with normal coronary arteriesArch Intern MedYear: 1988148145033377627
134. Gowda RM,Khan IA,Soodini G,Vasavada BC,Sacchi TJ. Acute myocardial infarction with normal coronary arteries associated with iatrogenic hyperthyroidismInt J CardiolYear: 200390327912957771
135. Patane S,Marte F. Atrial fibrillation and acute myocardial infarction without significant coronary stenoses associated with subclinical hyperthyroidism and erythrocytosisInt J CardiolYear: 2009 (Article in press).
136. Patane S,Marte F,Curro A,Cimino C. Recurrent acute pulmonary embolism and paroxysmal atrial fibrillation associated with subclinical hyperthyroidismInt J CardiolYear: 2010142e25619135742
137. Liberopoulos E,Miltiadous G,Elisaf M. Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidismDiabetes Obes MetabYear: 2001397811298731
138. Liberopoulos EN,Elisaf MS. Dyslipidemia in patients with thyroid disordersHormones (Athens)Year: 200212182317018450
139. Danese MD,Powe NR,Sawin CT,Ladenson PW. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysisJAMAYear: 1996276285928656540
140. Ladenson PW,Singer PA,Ain KB,et al. American Thyroid Association guidelines for detection of thyroid dysfunctionArch Intern MedYear: 20001601573510847249
141. U.S. Preventive Services Task ForceScreening for thyroid disease: recommendation statementAnn Intern MedYear: 2004140125714734336

Article Categories:
  • Article

Keywords: Keywords Cardiovascular disease, dyslipidemia, hypothyroidism, hyperthyroidism, lipoprotein (a), thyroid autoimmunity, thyroid dysfunction, thyroxine treatment..

Previous Document:  Chronic Proliferative Dermatitis in Mice: NF?B Activation Autoinflammatory Disease.
Next Document:  The Link between Cognitive Measures and ADLs and IADL Functioning in Mild Alzheimer's: What Has Gend...